Patients with hypertension
Conditions
Interventions
ARBs (select one from the following agents) Olemesartan 10-40mg/day Losaratan 25-100mg/day Telmisaratn 20-80mg/day The assessement will be done at baseline, 3, 6 and 12 months after the treatme
Sponsors
Second Department of Internal Medicine, Nagasaki University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients with hypertension who was diagnosed as active treatment with antihypertensive agents or as systolic blood pressure of >= 140 mmHg and/or diastolic blood pressure of >= 90 mmHg on at least 2 occasions.
Exclusion criteria
Exclusion criteria: Severe liver, renal or respiratory diseases Active infectious and inflammatory diseases Acute phase of heart failure Unstable angina Secondary hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effects of ARBs on the parameters listed below at baseline, 3, 6, and 12 months after the administrations. (1) Blood samples (lipid profiles, glucose tolerance, high-sensitive CRP, BNP, etc.) (2) Oxidative stress marker (8-OHdG, 8-isoprostane, etc.) (3) Electrocardiography (4) Echocardiography (5) Carotid ultrasonography (6) Pulse wave velocity | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of newly developed oxidative stress marker, such as oxidative LDL (negatively charged LDL) and glutathionylated protein | — |
Countries
Japan
Contacts
Public ContactSatoshi Ikeda
Nagasaki University School of Medicine Second Department of Internal Medicine
Outcome results
None listed